Chicago, IL (PRWEB) June 29, 2014
“Patients must understand the vital role they can play in advancing kidney cancer research,” says Bill Bro, CEO of the Kidney Cancer Association, a voluntary health organization that serves families worldwide.
The Chicago based charity has launched a campaign to educate families about how participating in a clinical trial helps to speed new cancer treatments from the laboratory to the bedside. The latest in a series of videos promoting the value of clinical trials is featured on the charity’s home page at http://www.KidneyCancer.org.
“We've seen an unprecedented rollout of new therapies for the treatment of advanced kidney cancer over the past seven years,” Bro adds. “None of this would have happened without the voluntary participation of thousands of patients in clinical trials. But, with these advancements, it has become more difficult to find previously untreated people with advanced disease who are willing to participate in clinical research. This slows progress, so we’re trying to spread the word about the value of clinical trials.”
Each month, the Kidney Cancer Association plans to feature information about clinical trials on its website’s home page, as well as through various social media. To learn about the trial featured in the video currently highlighted, interested individuals may visit this website: http://adaptkidneycancer.com/about-the-adapt-study/.
The Kidney Cancer Association is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. It is the world’s first international charity dedicated specifically to the eradication of death and suffering from renal cancers. It is also by far the largest organization of its kind, with members in more than 100 countries. It funds, promotes, and collaborates with the National Cancer Institute (NCI), American Society for Clinical Oncology (ASCO), American Urological Association (AUA), and other institutions on research projects. It educates families and physicians, and serves as an advocate on behalf of patients at the state and federal levels in the United States and globally.